(Q44551425)

English

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

scientific article published in March 2004

Statements

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. (English)
Michael B Atkins
Walter M Stadler
Theodore F Logan
Janice P Dutcher
Gary R Hudes
Young Park
Song-Heng Liou
Bonnie Marshall
Joseph P Boni
Gary Dukart
Matthew L Sherman
1 March 2004
909-918

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit